Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Los artículos de esta sección se muestran en inglés.
Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Cable de Trade News del 2026-08-05: Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies. Fuente primaria: original en CNBC Finance (cnbc.com).
Lee también
Labubu maker Pop Mart shares fall as key ex-China sales data drop, Citi cuts price target
Alibaba shares fall 4% as AI spending drives 75% drop in net income
